48,833
edits
(tweak formating) |
m (→Microscopic: wikify) |
||
Line 66: | Line 66: | ||
***ER staining will be heterologous in a benign lesion. | ***ER staining will be heterologous in a benign lesion. | ||
***Myoepithelial markers (calponin/p63/SMA +ve)s hould be positive in a benign lesion. | ***Myoepithelial markers (calponin/p63/SMA +ve)s hould be positive in a benign lesion. | ||
*[[Papillary ductal carcinoma in situ]] | *[[Papillary ductal carcinoma in situ]]. | ||
**Papillary DCIS shows myoepithelial cells (calponin/p63/SMA +ve) at the periphery of the involved spaces | **Papillary DCIS shows myoepithelial cells (calponin/p63/SMA +ve) at the periphery of the involved spaces | ||
**But papillary DCIS should be negative for myoepithelial cells within the focus of DCIS | **But papillary DCIS should be negative for myoepithelial cells within the focus of DCIS | ||
**Papillary intracystic carcinoma does not show myoepithelial cells at the periphery of the involved spaces | **Papillary intracystic carcinoma does not show myoepithelial cells at the periphery of the involved spaces | ||
*Invasive papillary carcinoma of the breast | *[[Invasive papillary carcinoma of the breast]]. | ||
**Similar architecture but no cystic space, frankly invasive. | **Similar architecture but no cystic space, frankly invasive. | ||
**Very rare. | **Very rare. |
edits